Valuation: Telix Pharmaceuticals Limited

Market Cap 5.32B 3.68B 3.23B 2.98B 2.79B 5.23B 347B 35.75B 13.85B 171B 13.83B 13.52B 595B P/E 2026 *
1,052x
P/E 2027 * 111x
Enterprise Value 5.73B 3.96B 3.48B 3.21B 3B 5.63B 374B 38.49B 14.91B 184B 14.89B 14.56B 641B EV / Sales 2026 *
4.21x
EV / Sales 2027 * 3.62x
Free-Float
83.23%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Telix Pharmaceuticals Limited

1 day-2.10%
1 week+5.86%
Current month+17.81%
1 month+16.02%
3 months+18.81%
6 months+30.42%
Current year+37.05%
1 week 14.07
Extreme 14.07
16.06
1 month 12.17
Extreme 12.17
16.06
Current year 8.26
Extreme 8.26
16.06
1 year 8.26
Extreme 8.26
25.87
3 years 8.2
Extreme 8.2
31.97
5 years 3.55
Extreme 3.55
31.97
10 years 0.46
Extreme 0.46
31.97
Manager TitleAgeSince
Chief Executive Officer 51 2017-01-02
Director of Finance/CFO 60 2022-07-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 2026-05-10
Director/Board Member 68 2026-05-10
Director/Board Member 51 2017-01-02
Date Insider Type Main position Quantity % Market Cap.
06-10Buy

Director

10,200 0.0030%
05-25Free

Director

30,048 0.0089%
05-25Free

Director

21,597 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-2.04%+5.86%-37.93%+32.79% 3.68B
+1.67%+9.28%-5.05%+1.40% 45.45B
+4.95%+9.31%+363.86%+598.16% 36.09B
-0.64%+1.92%+3.08%+53.58% 30.81B
+0.44%+11.12%+17.47%-12.91% 30.98B
+0.23%-0.29%+13.24%+21.10% 24.62B
+9.90%+13.32% - - 14.78B
+1.40%+12.99%+67.11%+132.76% 14.65B
+1.88%+8.59%+13.76%+20.68% 13.3B
+2.38%+5.69%+95.85%+97.63% 12.65B
Average +2.01%+7.17%+59.04%+105.02% 22.7B
Weighted average by Cap. +2.06%+6.84%+75.88%+127.21%

Financials

2026 *2027 *
Net sales 1.36B 941M 827M 762M 712M 1.34B 88.82B 9.14B 3.54B 43.78B 3.53B 3.46B 152B 1.59B 1.1B 969M 892M 834M 1.57B 104B 10.71B 4.15B 51.29B 4.14B 4.05B 178B
Net income 5.83M 4.04M 3.54M 3.27M 3.05M 5.73M 381M 39.19M 15.18M 188M 15.15M 14.82M 652M 43.23M 29.91M 26.28M 24.21M 22.64M 42.46M 2.82B 290M 113M 1.39B 112M 110M 4.84B
Net Debt 408M 282M 248M 229M 214M 401M 26.65B 2.74B 1.06B 13.14B 1.06B 1.04B 45.66B 447M 310M 272M 251M 234M 439M 29.21B 3.01B 1.16B 14.4B 1.16B 1.14B 50.04B
Logo Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
Employees
1,152
Date Price Change Volume
26-06-25 A$15.36 -2.04% 333,276
26-06-25 A$15.68 -0.32% 1,745,963
26-06-24 A$15.73 +8.04% 3,701,343
26-06-23 A$14.56 +2.46% 1,878,642
26-06-22 A$14.21 -2.00% 1,273,119
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
15.68AUD
Average target price
23.36AUD
Spread / Average Target
+49.00%

Quarterly revenue - Rate of surprise